MCID: RLP002
MIFTS: 57

Relapsing-Remitting Multiple Sclerosis

Categories: Neuronal diseases

Aliases & Classifications for Relapsing-Remitting Multiple Sclerosis

MalaCards integrated aliases for Relapsing-Remitting Multiple Sclerosis:

Name: Relapsing-Remitting Multiple Sclerosis 12 15
Multiple Sclerosis, Relapsing-Remitting 44 73
Relapsing Remitting Multiple Sclerosis 29 6
Multiple Sclerosis Relapsing-Remitting 55
Relapsing-Remitting Ms 12
Rrms 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2378
MeSH 44 D020529
SNOMED-CT 68 426373005
UMLS 73 C0751967

Summaries for Relapsing-Remitting Multiple Sclerosis

Disease Ontology : 12 A multiple sclerosis that is characterized by relapse (attacks of symptom flare-ups) followed by remission (periods of recovery). Symptoms may vary from mild to severe, and relapses and remissions may last for days or months. More than 80 percent of people who have MS begin with relapsing-remitting cycles.

MalaCards based summary : Relapsing-Remitting Multiple Sclerosis, also known as multiple sclerosis, relapsing-remitting, is related to hematopoietic stem cell transplantation and chlamydia. An important gene associated with Relapsing-Remitting Multiple Sclerosis is NEAT1 (Nuclear Paraspeckle Assembly Transcript 1
Our results indicate that these lncRNAs may be involved in MS pathogenesis.
Dysfunction Pattern: Regulation [up-regulated]), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Natalizumab and Glatiramer Acetate have been mentioned in the context of this disorder. Affiliated tissues include t cells, brain and bone, and related phenotypes are hematopoietic system and growth/size/body region

Related Diseases for Relapsing-Remitting Multiple Sclerosis

Diseases related to Relapsing-Remitting Multiple Sclerosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 257)
# Related Disease Score Top Affiliating Genes
1 hematopoietic stem cell transplantation 31.4 IFNG IL10 TNF
2 chlamydia 30.9 IFNG IL10 TNF
3 idiopathic neutropenia 30.9 CCL5 IL10 TNF
4 meningoencephalitis 30.8 BDNF CCL5 MBP
5 optic neuritis 30.6 AQP4 MBP MOG TNF
6 neuromyelitis optica 30.2 AQP4 IL17A MBP MOG
7 lung disease 30.2 CCL5 IL10 MMP9 TNF
8 cytomegalovirus infection 30.1 CCL5 ICAM1 IFNG IL10 TNF
9 secondary progressive multiple sclerosis 30.0 HNRNPA1 IFNB1 IL10 IL4 MBP MMP9
10 acute disseminated encephalomyelitis 30.0 AQP4 IL10 MBP MOG
11 neuritis 29.2 AQP4 CCL5 IFNG IL4 MBP MOG
12 multiple sclerosis 26.3 AQP4 BDNF CCL5 FOXP3 ICAM1 IFNB1
13 punctate inner choroidopathy 11.0 IL10 TNF
14 mycoplasmal pneumonia 10.9 IFNG IL4
15 scorpion envenomation 10.9 CCL5 TNF
16 staphylococcal toxic shock syndrome 10.8 IFNG TNF
17 clonorchiasis 10.8 IFNG IL10 TNF
18 intermediate uveitis 10.8 IFNG IL10 TNF
19 marburg hemorrhagic fever 10.8 IFNB1 TNF
20 acute necrotizing encephalitis 10.8 FOXP3 IFNG
21 tropical endomyocardial fibrosis 10.8 IL10 IL4 TNF
22 hemorrhagic fever 10.8 IFNG IL10 TNF
23 trichosporonosis 10.8 IFNG IL17A TNF
24 aseptic meningitis 10.8 IFNG IL10 TNF
25 tungiasis 10.8 IL10 IL4 TNF
26 q fever 10.8 IFNG IL10 TNF
27 endomyocardial fibrosis 10.8 IL10 IL4 TNF
28 chronic inflammatory demyelinating polyradiculoneuropathy 10.8 IFNB1 IFNG IL17A
29 panuveitis 10.8 IL10 IL17A TNF
30 hyperlucent lung 10.8 IFNG IL10 IL4
31 mixed connective tissue disease 10.8 IFNG IL10 TNF
32 microscopic colitis 10.7 IFNG IL4 TNF
33 reactive arthritis 10.7 IFNG IL10 TNF
34 baylisascariasis 10.7 IFNG IL10 IL4
35 dengue hemorrhagic fever 10.7 IFNG IL10 TNF
36 autoimmune myocarditis 10.7 IFNG TNF
37 brain injury 10.7 BDNF IL10 MBP
38 aphthous stomatitis 10.7 IL10 IL4 TNF
39 buruli ulcer 10.7 IFNG IL10 IL4
40 microscopic polyangiitis 10.7 IL10 TNF
41 rheumatic heart disease 10.7 IL10 IL4 TNF
42 japanese encephalitis 10.7 CCL5 IFNB1 TNF
43 keratoconjunctivitis sicca 10.7 IL10 IL4 TNF
44 multifocal choroiditis 10.7 IL10 TNF
45 apple allergy 10.7 FOXP3 IL10 IL4
46 erythema multiforme 10.7 ICAM1 IFNG TNF
47 parasitic helminthiasis infectious disease 10.7 IL10 IL4 TNF
48 aggressive periodontitis 10.7 IL10 IL4 TNF
49 tonsillitis 10.7 IFNG IL4 TNF
50 pleurisy 10.7 ICAM1 IFNG TNF

Graphical network of the top 20 diseases related to Relapsing-Remitting Multiple Sclerosis:



Diseases related to Relapsing-Remitting Multiple Sclerosis

Symptoms & Phenotypes for Relapsing-Remitting Multiple Sclerosis

MGI Mouse Phenotypes related to Relapsing-Remitting Multiple Sclerosis:

46 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.37 IFNB1 CCL5 FOXP3 AQP4 ICAM1 IL10
2 growth/size/body region MP:0005378 10.36 FOXP3 AQP4 BDNF ICAM1 IL18 IL10
3 immune system MP:0005387 10.33 IFNB1 CCL5 FOXP3 AQP4 ICAM1 IL10
4 homeostasis/metabolism MP:0005376 10.32 TNF IFNB1 FOXP3 AQP4 BDNF ICAM1
5 cellular MP:0005384 10.3 TNF ICAM1 BDNF FOXP3 IL18 IL10
6 digestive/alimentary MP:0005381 10.28 FOXP3 AQP4 BDNF ICAM1 IL18 IL10
7 endocrine/exocrine gland MP:0005379 10.22 TNF BDNF ICAM1 FOXP3 AQP4 IL10
8 mortality/aging MP:0010768 10.22 TNF BDNF ICAM1 FOXP3 AQP4 IL18
9 nervous system MP:0003631 10.1 TNF ICAM1 AQP4 BDNF IL18 IL10
10 craniofacial MP:0005382 10.09 TNF BDNF FOXP3 IL10 IL17A IFNG
11 integument MP:0010771 10.09 TNF BDNF ICAM1 FOXP3 IL18 IL10
12 neoplasm MP:0002006 9.91 TNF ICAM1 IL10 IFNB1 IFNG MMP9
13 no phenotypic analysis MP:0003012 9.91 TNF IFNB1 FOXP3 AQP4 BDNF IL10
14 reproductive system MP:0005389 9.81 TNF BDNF FOXP3 IL10 IFNG MBP
15 respiratory system MP:0005388 9.65 FOXP3 AQP4 BDNF IL10 IFNG IL17A
16 vision/eye MP:0005391 9.4 FOXP3 AQP4 BDNF ICAM1 IL10 IL4

Drugs & Therapeutics for Relapsing-Remitting Multiple Sclerosis

Drugs for Relapsing-Remitting Multiple Sclerosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 326)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Natalizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 189261-10-7
2
Glatiramer Acetate Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 147245-92-9 3081884
3
Interferon beta-1b Approved Phase 4,Phase 3,Phase 2 145155-23-3
4
Interferon beta-1a Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 145258-61-3 6438354
5
alemtuzumab Approved, Investigational Phase 4,Phase 3,Phase 2 216503-57-0
6
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 83-43-2 6741
7
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-24-8 5755
8
Simvastatin Approved Phase 4,Phase 3 79902-63-9 54454
9
Dimethyl fumarate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 624-49-7 5271565 637568
10
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
11
Acetaminophen Approved Phase 4,Phase 3 103-90-2 1983
12
Acyclovir Approved Phase 4,Phase 3 59277-89-3 2022
13
Cetirizine Approved Phase 4 83881-51-0 2678
14
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7 4594 9579578
15
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2 75614-87-8, 51-45-6 774
16
Ibuprofen Approved Phase 4 15687-27-1 3672
17
Ranitidine Approved Phase 4,Phase 3 66357-59-3, 66357-35-5 3001055
18
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
19
Iron Approved Phase 4 7439-89-6 23925
20 Titanium dioxide Approved Phase 4 13463-67-7
21
Donepezil Approved Phase 4 120014-06-4 3152
22
Mitoxantrone Approved, Investigational Phase 4,Phase 2 65271-80-9 4212
23
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 126941
24
Prednisone Approved, Vet_approved Phase 4,Phase 2 53-03-2 5865
25
Citalopram Approved Phase 4 59729-33-8 2771
26
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
27
Norepinephrine Approved Phase 4 51-41-2 439260
28
Loperamide Approved Phase 4 53179-11-6 3955
29
Simethicone Approved Phase 4 8050-81-5
30
Tretinoin Approved, Investigational, Nutraceutical Phase 4 302-79-4 5538 444795
31
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 11103-57-4, 68-26-8 445354
32
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 1,Not Applicable 50-14-6 5280793
33
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1406-16-2
34
Vitamin D3 Approved, Nutraceutical Phase 4,Phase 3,Phase 1,Not Applicable 67-97-0 6221 5280795
35
Menadione Approved, Nutraceutical Phase 4,Phase 3 58-27-5 4055
36
Phytonadione Approved, Investigational, Nutraceutical Phase 4,Phase 3 84-80-0 4812 5284607
37
Tocopherol Approved, Investigational, Nutraceutical Phase 4 1406-66-2 14986
38
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
39
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
40
leucovorin Approved, Nutraceutical Phase 4 58-05-9 143 6006
41 Fingolimod Hydrochloride Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43 Adjuvants, Immunologic Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
44 Antirheumatic Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
45 Antioxidants Phase 4,Phase 1,Phase 2
46 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
47 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1
48 Retinol palmitate Phase 4
49 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 Vitamins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 474)
# Name Status NCT ID Phase Drugs
1 Study to Assess Immune Function and MRI Disease Activity in RRMS Patients When Switching From Natalizumab to Gilenya Unknown status NCT02325440 Phase 4 Fingolimod;Natalizumab
2 Optical Coherence Tomography: Glatiramer in Clinically Isolated Syndrome or Early Relapsing Remitting Multiple Sclerosis (MS) Unknown status NCT00910598 Phase 4 glatiramer acetate
3 Impact of Vitamin A on RAR Gene Expression in Multiple Sclerosis Unknown status NCT01705457 Phase 4 Dietary Supplement: vitamin A;placebo
4 Impact of Vitamin A on Multiple Sclerosis (MS) Unknown status NCT01417273 Phase 4 Drug: placebo
5 Impact of Vitamin A on Gene Expression, in Multiple Sclerosis Patient Unknown status NCT01407211 Phase 4
6 Colecalciferol as an Add-on Treatment to Interferon-beta-1b for Treatment of Multiple Sclerosis (MS) Unknown status NCT01339676 Phase 4 Colecalciferol;Placebo capsules
7 Gastrointestinal Tolerability Study Of Dimethyl Fumarate In Participants With Relapsing-Remitting Multiple Sclerosis In Germany Completed NCT02125604 Phase 4 dimethyl fumarate
8 Phase 4 Study of Effect of Aspirin on Flushing in Dimethyl Fumarate-Treated Participants With Relapsing-Remitting Multiple Sclerosis Completed NCT02090413 Phase 4 dimethyl fumarate;acetylsalicylic acid;ASA-Placebo
9 Biomarker Study After Initiation of Treatment With Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis Completed NCT01310166 Phase 4 Fingolimod
10 A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Completed NCT00871780 Phase 4 BG00002 (natalizumab)
11 Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis. Completed NCT01623596 Phase 4 Fingolimod;Disease Modifying therapy
12 Safety Study in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Receiving Betaferon or Rebif Completed NCT00317941 Phase 4 Betaferon/Betaseron;Rebif;Betaferon/Betaseron
13 Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC) Completed NCT01534182 Phase 4 Fingolimod;Interferon beta - 1a (IFN);Glatiramer acetate (GA)
14 Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis Completed NCT00078338 Phase 4 Rebif®;Copaxone®
15 Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying Therapy Completed NCT01498887 Phase 4 Fingolimod (FTY720)
16 Safety and Efficacy of Natalizumab (BG00002, Tysabri®) in Russian Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Completed NCT02142205 Phase 4
17 Plegridy Satisfaction Study in Participants Completed NCT02587065 Phase 4 peginterferon beta-1a
18 Natalizumab De-escalation With Interferon Beta-1b Completed NCT01144052 Phase 4 interferon beta-1b;Natalizumab
19 Evaluation of Emotional Disorders During Treatment by Interferon Beta in Relapsing-remitting Multiple Sclerosis Patients Completed NCT01201343 Phase 4 Interferon beta-1a
20 A Phase 4 Study to Assess the Impact of Patient Support Program on Health Related Quality of Life and Adherence in Subjects With Relapsing-Remitting Multiple Sclerosis Administered Rebif® With the RebiSmart™ Device Completed NCT01791244 Phase 4 Rebif®
21 Follow up Study of Patients on Fingolimod Who Were Enrolled in the Original Biobank Study (CFTY720DDE01) Completed NCT02720107 Phase 4
22 Fingolimod Effect on Cytokine and Chemokine Levels Completed NCT02373098 Phase 4 Fingolimod 0.5 mg
23 Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA Completed NCT02205489 Phase 4 Alemtuzumab GZ402673;cetirizine;ranitidine;methylprednisolone;methylprednisolone;aciclovir;esomeprazole;ibuprofen;paracetamol
24 Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy Change Completed NCT01317004 Phase 4 Fingolimod;Standard MS DMT
25 Is IFN-beta Treatment in MS Useful After a Washout Period in Patients With Neutralizing Antibodies to Interferon Beta Completed NCT00493116 Phase 4 Interferon-beta-1a;methylprednisolone
26 Investigating if Interferon-Beta Can be Used in Patients With MS After They Have Developed Neutralizing Antibodies Completed NCT00492466 Phase 4 Interferon-beta-1a;methylprednisolone
27 Study To Evaluate The Immunogenicity And Safety Of r-hIFN Beta-1a (Rebif®) Using Clone 484-39 In Multiple Sclerosis Completed NCT00367484 Phase 4
28 Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS Completed NCT00168766 Phase 4 Interferon-beta-1a (Avonex) plus methylprednisolone
29 Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis Treated With Copaxone® Completed NCT02499900 Phase 4 Copaxone®
30 MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone Completed NCT01633112 Phase 4 fingolimod;copaxone
31 Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis Completed NCT00492765 Phase 4 Interferon-beta-1a;Simvastatin;Placebo
32 Does Quality of Life Improve in Multiple Sclerosis Patients Treated With Interferon Beta-1a? Completed NCT00534261 Phase 4 Interferon beta-1a
33 Fingolimod -Response According to Coping - Evaluation Completed NCT01420055 Phase 4 fingolimod
34 FOCUS Fatigue Outcome in Copaxone USers Completed NCT00267319 Phase 4 Glatiramer acetate
35 Safety and Efficacy Study of Doxycycline in Combination With Interferon-B-1a to Treat Multiple Sclerosis Completed NCT00246324 Phase 4 Interferon beta 1a, oral doxycycline
36 Rebif Advanced Magnetic Resonance Imaging (MRI) and Immunology Pilot Trial Completed NCT01085318 Phase 4 Rebif
37 Rebif® Rebidose® Versus Rebiject II® Ease-of-Use Completed NCT02019550 Phase 4
38 Effects of Vitamin K on Redness Associated With Injection Site Reactions in Participants Treated With Plegridy Completed NCT03091569 Phase 4
39 Efficacy of Fish Oil in Multiple Sclerosis Completed NCT01842191 Phase 4
40 Impact of Vitamin A Supplementation on Immune System in Multiple Sclerosis Patients Completed NCT01225289 Phase 4 Placebo
41 A fMRI(Functional Magnetic Resonance Imaging) Research Study to Learn More About Multiple Sclerosis and Individuals Potentially Experiencing Memory Difficulties Completed NCT00315367 Phase 4 Donepezil HCI (drug)
42 Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms Completed NCT01333501 Phase 4 Fingolimod;Interferon beta 1b
43 STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START) Completed NCT01585298 Phase 4 FTY720
44 An Efficacy and Safety Comparison Study of Two Marketed Drugs in Patients With Relapsing-remitting MS Completed NCT00206648 Phase 4 Betaferon/Betaseron;Betaferon/Betaseron
45 A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic’s Disease) Completed NCT00304291 Phase 4 Mitoxantrone
46 A 12 -Month, Open-label, Multi-center Study to Explore the Health Outcomes of FTY720 Completed NCT01578330 Phase 4 Fingolimod
47 Oral Corticotherapy in Megadoses to Treat Multiple Sclerosis During Relapse Completed NCT00753792 Phase 4 methylprednisolone;methylprednisolone;Placebo
48 Long-term Follow-up of Fingolimod Phase II Study Patients Completed NCT02307838 Phase 4
49 A Study of Rebif® in Subjects With Relapsing Multiple Sclerosis Completed NCT02064816 Phase 4 Rebif®;Rebif®
50 A Phase IV Study of Rebif ® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone Completed NCT01142466 Phase 4 Interferon beta-1a (Rebif)

Search NIH Clinical Center for Relapsing-Remitting Multiple Sclerosis

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: multiple sclerosis, relapsing-remitting

Genetic Tests for Relapsing-Remitting Multiple Sclerosis

Genetic tests related to Relapsing-Remitting Multiple Sclerosis:

# Genetic test Affiliating Genes
1 Relapsing Remitting Multiple Sclerosis 29

Anatomical Context for Relapsing-Remitting Multiple Sclerosis

MalaCards organs/tissues related to Relapsing-Remitting Multiple Sclerosis:

41
T Cells, Brain, Bone, Testes, Monocytes, B Cells, Spinal Cord

Publications for Relapsing-Remitting Multiple Sclerosis

Articles related to Relapsing-Remitting Multiple Sclerosis:

(show top 50) (show all 779)
# Title Authors Year
1
Cortical Excitability and Interhemispheric Connectivity in Early Relapsing-Remitting Multiple Sclerosis Studied With TMS-EEG. ( 29937712 )
2018
2
Addressing the targeting range of the ABILHAND-56 in relapsing-remitting multiple sclerosis: A mixed methods psychometric study. ( 29796290 )
2018
3
Focal cortical thinning in patients with stable relapsing-remitting multiple sclerosis: cross-sectional-based novel estimation of gray matter kinetics. ( 29285552 )
2018
4
Profiling of Canonical and Non-Traditional Cytokine Levels in Interferon-I^-Treated Relapsing-Remitting-Multiple Sclerosis Patients. ( 29915590 )
2018
5
An epidemiological study on the course of disease and therapeutic considerations in relapsing-remitting multiple sclerosis patients receiving injectable first-line disease-modifying therapies in Germany (EPIDEM). ( 29399053 )
2018
6
Longitudinal analysis of verbal episodic memory in patients with relapsing-remitting multiple sclerosis. ( 29898076 )
2018
7
Argentinean recommendations on the identification of treatment failure in relapsing remitting multiple sclerosis patients. ( 29406907 )
2018
8
Primary cytomegalovirus infection in a patient with relapsing-remitting multiple sclerosis under treatment with alemtuzumab. ( 29907474 )
2018
9
Real Life Long-Term Effectiveness of Fingolimod in Swiss Patients with Relapsing-Remitting Multiple Sclerosis (REALITE). ( 29431876 )
2018
10
Lower 25-Hydroxyvitamin D Is Associated with Higher Relapse Risk in Patients with Relapsing-Remitting Multiple Sclerosis. ( 29300420 )
2018
11
Late onset and young onset relapsing remitting multiple sclerosis. Evidence from a retrospective long-term follow-up study. ( 29956427 )
2018
12
Socio-economic status influences access to second-line disease modifying treatment in Relapsing Remitting Multiple Sclerosis patients. ( 29390025 )
2018
13
Tolerability and Safety Profile of a New Brand-Generic Product of Glatiramer Acetate in Iranian Patients with Relapsing-Remitting Multiple Sclerosis: An Observational Cohort Study. ( 29928468 )
2018
14
Natural Killer Cells Regulate Th17 Cells After Autologous Hematopoietic Stem Cell Transplantation for Relapsing Remitting Multiple Sclerosis. ( 29867923 )
2018
15
Circulating levels of interleukin-17A, tumor necrosis factor-alpha, interleukin-18, interleukin-10, and cognitive performance of patients with relapsing-remitting multiple sclerosis. ( 29297273 )
2018
16
Effects of lipoic acid on migration of human B cells and monocyte-enriched peripheral blood mononuclear cells in relapsing remitting multiple sclerosis. ( 29306401 )
2018
17
Thalamus volume change and cognitive impairment in early relapsing-remitting multiple sclerosis patients. ( 29869576 )
2018
18
Relapsing-Remitting Multiple Sclerosis Is Characterized by a T Follicular Cell Pro-Inflammatory Shift, Reverted by Dimethyl Fumarate Treatment. ( 29896193 )
2018
19
Synchronization within, and interactions between, the default mode and dorsal attention networks in relapsing-remitting multiple sclerosis. ( 29795982 )
2018
20
Response to 'Does cladribine have an impact on brain atrophy in people with relapsing remitting multiple sclerosis?' by Schiffmann et al. ( 29308979 )
2018
21
Cortical and Subcortical Morphometric and Iron Changes in Relapsing-Remitting Multiple Sclerosis and Their Association with White Matter T2A Lesion Load : AA 3-Tesla Magnetic Resonance Imaging Study. ( 29299614 )
2018
22
Biomarkers identification for PML monitoring, during Natalizumab (TysabriAr) treatment in Relapsing-Remitting Multiple Sclerosis. ( 29353737 )
2018
23
Pharmacokinetic drug evaluation of daclizumab for the treatment of relapsing-remitting multiple sclerosis. ( 29363337 )
2018
24
Dietary approaches to treat MS-related fatigue: comparing the modified Paleolithic (Wahls Elimination) and low saturated fat (Swank) diets on perceived fatigue in persons with relapsing-remitting multiple sclerosis: study protocol for a randomized controlled trial. ( 29866196 )
2018
25
Cost-minimization analysis of alemtuzumab compared to fingolimod and natalizumab for the treatment of active relapsing-remitting multiple sclerosis in the Netherlands. ( 29911917 )
2018
26
When does economic model type become a decisive factor in health technology appraisals? Learning from the expanding treatment options for relapsing-remitting multiple sclerosis. ( 29923439 )
2018
27
Relapsing-Remitting Multiple Sclerosis diagnosis from cerebrospinal fluids via Fourier transform infrared spectroscopy coupled with multivariate analysis. ( 29348591 )
2018
28
Mortality from Listeria monocytogenes meningoencephalitis following escalation to alemtuzumab therapy for relapsing-remitting Multiple Sclerosis. ( 29885597 )
2018
29
Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing-remitting multiple sclerosis: the CLARITY Extension study. ( 29399054 )
2018
30
Preservation of neuronal function as measured by clinical and MRI endpoints in relapsing-remitting multiple sclerosis: how effective are current treatment strategies? ( 29411688 )
2018
31
Corrigendum to "Argentinean recommendations on the identification of treatment failure in relapsing remitting multiple sclerosis patients" [J. Neurol. Sci. 385C (2018) 217-224]. ( 29449007 )
2018
32
Immunomodulatory function of Treg-derived exosomes is impaired in patients with relapsing-remitting multiple sclerosis. ( 29882035 )
2018
33
Modeling Approaches in Cost-Effectiveness Analysis of Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: An Updated Systematic Review and Recommendations for Future Economic Evaluations. ( 29971666 )
2018
34
Does cladribine have an impact on brain atrophy in people with relapsing remitting multiple sclerosis? ( 29308975 )
2018
35
A Pediatric Case of Relapsing-Remitting Multiple Sclerosis Onset following Varicella Zoster Ophthalmicus with Optic Neuritis. ( 29785316 )
2018
36
JCPyV microRNA in plasma inversely correlates with JCPyV seropositivity among long-term natalizumab-treated relapsing-remitting multiple sclerosis patients. ( 28831768 )
2017
37
Assessing 'No Evidence of Disease Activity' Status in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Fingolimod in Routine Clinical Practice: A Retrospective Analysis of the Multiple Sclerosis Clinical and Magnetic Resonance Imaging Outcomes in the USA (MS-MRIUS) Study. ( 29270772 )
2017
38
Alterations in serum levels of IL-17 in contrast to TNF-alpha correspond to disease-modifying treatment in relapsing-remitting multiple sclerosis. ( 28319417 )
2017
39
Relapse outcomes, safety, and treatment patterns in patients diagnosed with relapsing-remitting multiple sclerosis and initiated on subcutaneous interferon I^-1a or dimethyl fumarate: a real-world study. ( 28906152 )
2017
40
Trans-synaptic degeneration in the optic pathway. A study in clinically isolated syndrome and early relapsing-remitting multiple sclerosis with or without optic neuritis. ( 28850630 )
2017
41
A discrete event simulation to model the cost-utility of fingolimod and natalizumab in rapidly evolving severe relapsing-remitting multiple sclerosis in the UK. ( 28008769 )
2017
42
Interleukin 7 Receptor Alpha Gene Variants Are Correlated with Gene Expression in Patients with Relapsing-remitting Multiple Sclerosis. ( 28865414 )
2017
43
Standardised Frankincense extract: new possible therapeutic option for patients with relapsing-remitting multiple sclerosis. ( 29275327 )
2017
44
An update on cladribine for relapsing-remitting multiple sclerosis. ( 28858531 )
2017
45
Efficacy and Tolerability of Delayed-release Dimethyl Fumarate in Black, Hispanic, and Asian Patients with Relapsing-Remitting Multiple Sclerosis: Post Hoc Integrated Analysis of DEFINE and CONFIRM. ( 28770420 )
2017
46
Peginterferon beta-1a reduces disability worsening in relapsing-remitting multiple sclerosis: 2-year results from ADVANCE. ( 28450894 )
2017
47
Multiple sclerosis: Intrathecal inflammation mediates mood in relapsing-remitting multiple sclerosis. ( 28914885 )
2017
48
Interferon beta-1b in treatment-naA^ve paediatric patients with relapsing-remitting multiple sclerosis: Two-year results from the BETAPAEDIC study. ( 29318028 )
2017
49
Comparison of efficacy and safety of oral agents for the treatment of relapsing-remitting multiple sclerosis. ( 28814828 )
2017
50
High serum levels of BMP-2 correlate with BMP-4 and BMP-5 levels and induce reduced neuronal phenotype in patients with relapsing-remitting multiple sclerosis. ( 28778435 )
2017

Variations for Relapsing-Remitting Multiple Sclerosis

ClinVar genetic disease variations for Relapsing-Remitting Multiple Sclerosis:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 HNRNPA1 NM_002136.3(HNRNPA1): c.826A> C (p.Met276Leu) single nucleotide variant Likely pathogenic rs483353024 GRCh37 Chromosome 12, 54677670: 54677670
2 HNRNPA1 NM_002136.3(HNRNPA1): c.826A> C (p.Met276Leu) single nucleotide variant Likely pathogenic rs483353024 GRCh38 Chromosome 12, 54283886: 54283886
3 HNRNPA1 NM_002136.3(HNRNPA1): c.839A> G (p.Asn280Ser) single nucleotide variant Likely pathogenic rs3207617 GRCh37 Chromosome 12, 54677683: 54677683
4 HNRNPA1 NM_002136.3(HNRNPA1): c.839A> G (p.Asn280Ser) single nucleotide variant Likely pathogenic rs3207617 GRCh38 Chromosome 12, 54283899: 54283899

Expression for Relapsing-Remitting Multiple Sclerosis

Search GEO for disease gene expression data for Relapsing-Remitting Multiple Sclerosis.

Pathways for Relapsing-Remitting Multiple Sclerosis

Pathways related to Relapsing-Remitting Multiple Sclerosis according to GeneCards Suite gene sharing:

(show all 50)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.06 CCL5 ICAM1 IFNB1 IFNG IL10 IL17A
2
Show member pathways
13.71 BDNF CCL5 IFNB1 IFNG IL10 IL17A
3
Show member pathways
13.52 BDNF CCL5 IFNB1 IFNG IL10 IL17A
4
Show member pathways
13.43 BDNF CCL5 IL10 IL17A IL18 IL4
5
Show member pathways
13.33 BDNF CCL5 IL10 IL17A IL18 IL4
6
Show member pathways
13.26 CCL5 ICAM1 IFNB1 IFNG IL10 IL17A
7
Show member pathways
13.03 CCL5 IFNB1 IFNG IL10 IL18 TNF
8
Show member pathways
12.92 FOXP3 ICAM1 IFNG IL10 IL17A IL18
9
Show member pathways
12.85 CCL5 ICAM1 IFNB1 IFNG IL18 IL4
10
Show member pathways
12.76 CCL5 IFNB1 IFNG IL18 TNF
11
Show member pathways
12.65 IFNB1 IFNG IL10 IL17A IL18 IL4
12 12.63 CCL5 FOXP3 IFNG IL10 IL17A IL4
13
Show member pathways
12.61 IFNG IL10 IL17A IL18 TIMP1 TNF
14
Show member pathways
12.54 ICAM1 IFNB1 IFNG IL4 TNF
15
Show member pathways
12.5 FOXP3 IFNG IL10 IL17A IL18 IL4
16
Show member pathways
12.46 IFNG IL10 IL17A IL4 TNF
17
Show member pathways
12.37 CCL5 ICAM1 IFNG IL4 TNF
18
Show member pathways
12.36 IFNG IL17A IL4 MMP9 TNF
19
Show member pathways
12.29 IFNG IL10 IL17A IL18 TNF
20
Show member pathways
12.27 IFNG IL10 IL4 TNF
21 12.26 IFNB1 IFNG IL10 IL18 TNF
22
Show member pathways
12.21 IFNB1 IFNG IL4 TNF
23 12.2 AQP4 BDNF IL10 TNF
24 12.12 ICAM1 IFNG MMP9 TNF
25 12.03 IFNG IL10 IL4 TNF
26 11.99 CCL5 ICAM1 MMP9 TNF
27 11.93 CCL5 ICAM1 IFNG IL17A IL18 TNF
28
Show member pathways
11.92 BDNF CCL5 ICAM1 IFNG IL10 IL17A
29 11.87 IFNG IL10 TNF
30
Show member pathways
11.85 FOXP3 ICAM1 IL17A
31 11.84 AQP4 BDNF ICAM1 IFNG IL4 MBP
32
Show member pathways
11.81 FOXP3 IFNG IL4 TNF
33 11.81 IFNG IL10 IL17A IL18 IL4 TNF
34 11.79 ICAM1 IFNG IL4
35 11.79 IFNB1 IFNG IL10 TNF
36 11.74 CCL5 IL4 MMP9 TIMP1 TNF
37
Show member pathways
11.7 ICAM1 IFNG MMP9 TNF
38 11.61 ICAM1 IFNG IL10 IL18 TNF
39 11.61 ICAM1 IL10 IL17A IL18 IL4 MMP9
40 11.56 FOXP3 IFNG IL10 IL4
41 11.54 ICAM1 MMP9 TNF
42 11.54 IFNG IL18 TNF
43 11.45 ICAM1 IFNG IL10 IL18 TNF
44 11.42 ICAM1 IFNB1 IFNG
45 11.38 IFNG IL17A IL18 IL4 TNF
46 11.28 IFNB1 IFNG IL10 IL4 TNF
47 11.24 IFNG IL10 IL4
48 11.2 CCL5 IFNB1 TNF
49 11.12 ICAM1 IFNG IL18 MMP9 TIMP1
50 10.86 CCL5 ICAM1 IL10 IL18 IL4 TIMP1

GO Terms for Relapsing-Remitting Multiple Sclerosis

Cellular components related to Relapsing-Remitting Multiple Sclerosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.7 BDNF CCL5 IFNB1 IFNG IL10 IL17A
2 external side of plasma membrane GO:0009897 9.55 AQP4 ICAM1 IL17A MOG TNF
3 extracellular space GO:0005615 9.4 BDNF CCL5 ICAM1 IFNB1 IFNG IL10

Biological processes related to Relapsing-Remitting Multiple Sclerosis according to GeneCards Suite gene sharing:

(show all 38)
# Name GO ID Score Top Affiliating Genes
1 MAPK cascade GO:0000165 9.98 CCL5 IL18 MBP TNF
2 immune response GO:0006955 9.86 CCL5 IFNG IL10 IL17A IL18 IL4
3 cellular response to interferon-gamma GO:0071346 9.85 AQP4 CCL5 ICAM1
4 cellular response to interleukin-1 GO:0071347 9.83 CCL5 ICAM1 IL17A
5 cellular response to organic cyclic compound GO:0071407 9.83 CCL5 IL18 TNF
6 B cell differentiation GO:0030183 9.82 IFNB1 IL10 IL4
7 regulation of insulin secretion GO:0050796 9.82 CCL5 IFNG TNF
8 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.81 CCL5 IFNG IL18
9 humoral immune response GO:0006959 9.79 IFNB1 IFNG TNF
10 positive regulation of smooth muscle cell proliferation GO:0048661 9.77 CCL5 IL18 TNF
11 positive regulation of nitric oxide biosynthetic process GO:0045429 9.73 ICAM1 IFNG TNF
12 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.71 IL10 MMP9 TNF
13 negative regulation of endothelial cell apoptotic process GO:2000352 9.7 ICAM1 IL10 IL4
14 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.67 IL10 TNF
15 negative regulation of interleukin-17 production GO:0032700 9.67 FOXP3 IFNG
16 negative regulation of viral genome replication GO:0045071 9.67 CCL5 IFNB1 MX1 TNF
17 neutrophil activation GO:0042119 9.66 CCL5 IL18
18 negative regulation of heterotypic cell-cell adhesion GO:0034115 9.65 IL10 MBP
19 lipopolysaccharide-mediated signaling pathway GO:0031663 9.65 CCL5 IL18 TNF
20 regulation of signaling receptor activity GO:0010469 9.65 BDNF CCL5 IFNB1 IFNG IL10 IL17A
21 negative regulation of membrane protein ectodomain proteolysis GO:0051045 9.63 IL10 TIMP1
22 endothelial cell apoptotic process GO:0072577 9.63 IL10 TNF
23 negative regulation of interleukin-6 production GO:0032715 9.63 FOXP3 IL10 TNF
24 response to virus GO:0009615 9.63 CCL5 FOXP3 IFNB1 IFNG MX1 TNF
25 positive regulation of MHC class II biosynthetic process GO:0045348 9.62 IL10 IL4
26 negative regulation of cytokine secretion involved in immune response GO:0002740 9.59 IL10 TNF
27 positive regulation of receptor binding GO:1900122 9.58 BDNF MMP9
28 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.58 ICAM1 TNF
29 positive regulation of osteoclast differentiation GO:0045672 9.58 IFNG